Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 4,516 matching trials from the live ClinicalTrials.gov search.
Filters: Lexington, Kentucky Clear all
Completed Phase 2 Interventional Results available

Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI)

NCT02819479
View directory record Official record
Conditions
Radiation Necrosis
Interventions
25% Mannitol, Low-dose Intra-arterial Bevacizumab
Drug
Lead sponsor
Norton Healthcare
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Lexington, Kentucky • Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Oct 22, 2026, 2:45 PM EDT
Completed Phase 3 Interventional Results available

Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)

NCT02227862
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Mylan's insulin glargine, Lantus®
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
72
States / cities
Bell Gardens, California • Fresno, California • Greenbrae, California + 64 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 22, 2026, 2:45 PM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

NCT07453888
View directory record Official record
Conditions
Non-Arteritic Anterior Ischemic Optic Neuropathy
Interventions
Cenegermin, Vehicle
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
50 Years to 80 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
22
States / cities
Los Angeles, California • Newport Beach, California • Aurora, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 22, 2026, 2:45 PM EDT
Completed Phase 4 Interventional Results available

A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine

NCT05127486
View directory record Official record
Conditions
Migraine, Episodic Migraine
Interventions
Galcanezumab, Rimegepant, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
77
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tempe, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2024 · Synced Oct 22, 2026, 2:45 PM EDT
Recruiting Phase 2 Interventional

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

NCT06031688
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Lymphoscintigraphy, Magnetic Resonance Imaging, Ramucirumab, Tepotinib
Procedure · Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Minutes and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
278
States / cities
Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 232 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 22, 2026, 2:45 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs

NCT03896503
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma, Extrapulmonary Small Cell Neuroendocrine Carcinoma, Limited Stage Lung Small Cell Carcinoma, Platinum-Resistant Lung Small Cell Carcinoma, Platinum-Sensitive Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma
Interventions
Berzosertib, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Topotecan Hydrochloride
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
33
States / cities
Los Angeles, California • Newport Beach, California • Sacramento, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 22, 2026, 2:45 PM EDT
Completed Phase 4 Interventional

Comparing Pre-Mixed Insulin With Insulin Glargine Combined With Rapid-Acting Insulin in Patients With Type 2 Diabetes

NCT00110370
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Lispro Mixture Therapy, Glargine Basal-Bolus Therapy
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
30 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
44
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2007 · Synced Oct 22, 2026, 2:45 PM EDT
Completed Phase 2 Interventional

Tirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

NCT00020696
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
cisplatin, tirapazamine
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
50
States / cities
Birmingham, Alabama • Los Angeles, California • Los Gatos, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2012 · Synced Oct 22, 2026, 2:45 PM EDT
Completed Phase 3 Interventional Results available

VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

NCT05780281
View directory record Official record
Conditions
COVID-19
Interventions
VIR-7831, Placebo, Remdesivir
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
74
States / cities
Tucson, Arizona • Fresno, California • Loma Linda, California + 50 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Oct 22, 2026, 2:45 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF)

NCT03150719
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Tezacaftor/Ivacaftor, Ivacaftor, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 22, 2026, 2:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluating an mHealth Intervention for Reducing Alcohol Use Among Adolescent and Young Adult Cancer Survivors

NCT05087875
View directory record Official record
Conditions
Cancer, Alcohol Use
Interventions
TRAC: Tracking and Reducing Alcohol Consumption, No intervention
Behavioral · Other
Lead sponsor
Carolyn Lauckner
Other
Eligibility
18 Years to 39 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Oct 22, 2026, 2:45 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse

NCT01967381
View directory record Official record
Conditions
Methamphetamine Abuse, Methamphetamine Dependence
Interventions
Methamphetamine (Desoxyn®)
Drug
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 14, 2018 · Synced Oct 22, 2026, 2:45 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

NCT05366881
View directory record Official record
Conditions
Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Esophageal Cancer, Stomach Cancer, Head and Neck Cancer, Hepatobiliary Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cancer, Sarcoma, Thyroid Cancer
Interventions
Not listed
Lead sponsor
Adela, Inc
Industry
Eligibility
40 Years and older
Enrollment
7,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
17
States / cities
Duarte, California • Miami, Florida • Gainesville, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 22, 2026, 2:45 PM EDT
Active, not recruiting Phase 3 Interventional

Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study

NCT02997228
View directory record Official record
Conditions
Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7
Interventions
Atezolizumab, Bevacizumab, Biospecimen Collection, Computed Tomography, Fluorouracil, Leucovorin, Magnetic Resonance Imaging, Oxaliplatin, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration
Drug · Biological · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
445
States / cities
Kingman, Arizona • Jonesboro, Arkansas • Anaheim, California + 346 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 22, 2026, 2:45 PM EDT
Completed Phase 2 Interventional Results available

Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma

NCT03304639
View directory record Official record
Conditions
Advanced Merkel Cell Carcinoma, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Metastatic Merkel Cell Carcinoma, Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
Interventions
Pembrolizumab, Stereotactic Body Radiation Therapy
Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
254
States / cities
Anchorage, Alaska • Tucson, Arizona • Fort Smith, Arkansas + 172 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 22, 2026, 2:45 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism

NCT00643201
View directory record Official record
Conditions
Venous Thrombosis
Interventions
Enoxaparin, warfarin, Placebo for apixaban, Placebo for enoxaparin, Placebo for warfarin, apixaban
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
5,614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
73
States / cities
Birmingham, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 68 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 22, 2026, 2:45 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

NCT05030428
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Inclisiran sodium 300 mg, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 100 Years
Enrollment
17,004 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
271
States / cities
Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 214 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 22, 2026, 2:45 PM EDT
Completed Not applicable Interventional

Telehealth Delivered Physical Rehabilitation for an Ankle Sprain

NCT04520854
View directory record Official record
Conditions
Ankle Sprains, Telerehabilitation, Analgesic, Opioid, Analgesics, Non-narcotic, Anti-Inflammatory Agents, Non-Steroidal, Implementation Science, Acute Pain, Quality of Life
Interventions
Telehealth Protocol, Usual Care
Other
Lead sponsor
Kyle Kosik
Other
Eligibility
15 Years to 35 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 22, 2026, 2:45 PM EDT
Completed No phase listed Observational Results available

MultiPoint Pacing™ Post Market Study

NCT02832622
View directory record Official record
Conditions
Heart Failure
Interventions
MPP, BiV/MPP
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
110
States / cities
Birmingham, Alabama • Huntsville, Alabama • Avondale, Arizona + 99 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 22, 2026, 2:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Promoting Quality of Life Among Young Adult Cancer Survivors

NCT03446105
View directory record Official record
Conditions
Cancer
Interventions
App-based behavioral intervention, Attention control group
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 39 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 10, 2018 · Synced Oct 22, 2026, 2:45 PM EDT
Completed Phase 2 Interventional

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

NCT02723994
View directory record Official record
Conditions
Leukemia
Interventions
Ruxolitinib, Asparaginase Erwinia Chrysanthemi, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Thioguanine, Vincristine Sulfate
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
1 Year to 21 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
103
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 87 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 22, 2026, 2:45 PM EDT
Completed Phase 2 Interventional

S0027: Vinorelbine Followed by Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer

NCT00026156
View directory record Official record
Conditions
Lung Cancer
Interventions
docetaxel, vinorelbine tartrate
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
96
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 22, 2026, 2:45 PM EDT
Terminated Phase 2 Interventional Results available

A Study Of CP-195543 And Celecoxib Dual Therapy In Subjects With Rheumatoid Arthritis

NCT00424294
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CP-195,543, celecoxib, Methotrexate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
39
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Upland, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 22, 2026, 2:45 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.

NCT04049266
View directory record Official record
Conditions
Wet Macular Degeneration
Interventions
KSI-301, Aflibercept, Sham Procedure
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
50 Years and older
Enrollment
559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
59
States / cities
Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 53 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Oct 22, 2026, 2:45 PM EDT